tp-0903
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 14, 2016 (NCT02729298)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase receptor UFOINHIBITOR
AXL inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN(Cc2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)N(C)C)n3)cc2)CC1- Mol. weight
- 516.07 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2022968 ↗
Also known as
- tp-0903
- tp-0903
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04518345 | Phase 1/Phase 2 (Phase 2) | Nov 5, 2020 | Ohio State University, Sumitomo |
| NCT03572634 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2018 | Tolero Pharmaceuticals |
| NCT02729298 | Phase 1 | Dec 14, 2016 | Tolero Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tolero Pharmaceuticals | For profit | 2 | 2 | 2 | 2016 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Sumitomo | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1